SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 31, 2009 between Capital Growth Systems, Inc., a Florida corporation (the “ Company ”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “ Purchaser ” and collectively, the “ Purchasers ”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act of 1933, as amended (the “ Securities Act ”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

1.1            Definitions .  In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Debentures (as defined herein), and (b) the following terms have the meanings set forth in this Section 1.1:

“ Acquiring Person ” shall have the meaning ascribed to such term in Section 4.7.

“ Action ” shall have the meaning ascribed to such term in Section 3.1(j).

“ Affiliate ” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

“ Authorized Share Approval ” means (i) the vote by the stockholders of the Company to approve an amendment to the Company’s articles or certificate of incorporation that increases the number of authorized shares of Common Stock to at least 990,000,000 shares of Common Stock (the “ Amendment ”) and (ii) the filing by the Company of the Amendment with the Secretary of State of the State of Florida and the acceptance of the Amendment by the Secretary of State of the State of Florida.

“ Board of Directors ” means the board of directors of the Company.

“ Business Day ” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

“ Closing ” means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

“ Closing Date ” means the Trading Day when all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Securities have been satisfied or waived.

“ Closing Statement ” means the Closing Statement in the form Annex A attached hereto.

“ Collateral Agent ” shall mean the collateral agent for the benefit of the Debenture holders, as named in the Security Agreement.

“ Commission ” means the United States Securities and Exchange Commission.

“ Common Stock ” means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed into.

“ Common Stock Equivalents ” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive Common Stock.

“ Company Counsel ” means Shefsky & Froelich, with offices located at 111 E. Wacker Drive, Suite 2800, Chicago, Illinois 60601.

“ Conversion Price ” shall have the meaning ascribed to such term in the Debentures.

“ Consent, Waiver and Amendment Agreement ” shall have the meaning set forth in Section 2.2 (b)(i) hereof.

“ Debentures ” means the Original Issue Discount Secured Convertible Debentures due, subject to the terms therein, due May 30, 2011, issued by the Company to the Purchasers hereunder, in the form of Exhibit A attached hereto.

“ Disclosure Schedules ” shall have the meaning ascribed to such term in Section 3.1.

“ Discussion Time ” shall have the meaning ascribed to such term in Section 3.2(f).

“ Effective Date ” means the earlier of (a) the effective date of a Registration Statement and (b) the date that all of Underlying Shares issuable pursuant to the Transaction Documents may be sold or are eligible for sale under Rule 144, without  volume or manner-of-sale restrictions.  In determining eligibility for sale under Rule 144, with respect to the Warrants, it is assumed that the Warrants shall be exercised pursuant to cashless exercise, so that the holding period for the Underlying Shares underlying the Warrants shall tack back to the holding period of the Warrants.

“ Evaluation Date ” shall have the meaning ascribed to such term in Section 3.1(r).

“ Exchange Act ” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“ Exempt Issuance ” means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise or exchange of or conversion of any Securities issued pursuant to the July Purchase Agreement or under the March Purchase Agreement (including but not limited to the Original Issue Discount Debentures expiring November 20, 2015 issued in exchange for the original debentures issued pursuant to that agreement), the November Purchase Agreement or the VPP Debenture Purchase Agreement (including but not limited to the issuance of Common Stock: (i) pursuant to Section 2.1 or Section 4.14 of the July Purchase Agreement; (ii) with respect to the redemption of the Debentures and the debentures issued pursuant to the March Purchase Agreement, the November Purchase Agreement or the VPP Purchase Agreement, or (iii) pursuant to payment of any liquidated damages with respect to the July Debentures, the July Warrants and the July Purchase Agreement and the debentures and warrants issued or issuable  pursuant to the March Purchase Agreement, November Purchase Agreement and VPP Purchase Agreement) and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a Person which is, itself or through its subsidiaries, an operating company in a business synergistic with the business of the Company and in which the Company receives benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (d) for purposes of Section 4.12 only, an issuance of Common Stock or Common Stock Equivalents, without registration rights, for cash consideration, to the global carrier referenced in the Company’s press release dated February 20, 2008, provided, however, any such issuance of Common Stock Equivalents shall be expressly subordinate to the Debentures pursuant to a written subordination agreement with the Purchasers that is acceptable to each Purchaser in its sole and absolute discretion; (e) outstanding Common Stock and Common Stock Equivalents as of the date hereof and all securities issuable in connection with them; and (f) for purposes of Sections 4.12 and 4.13 only, securities (including shares of Commons Stock, warrants and Common Stock Equivalents) issued in connection with the Senior Lender Loan Agreement, the terms of which are described in the Disclosure Schedules hereto).

“ GAAP ” shall have the meaning ascribed to such term in Section 3.1(h).

“ Holders ” shall mean the persons or entities holding the Debentures from time to time.

“ Indebtedness ” shall have the meaning ascribed to such term in Section 3.1(aa).

“ Intellectual Property Rights ” shall have the meaning ascribed to such term in Section 3.1(o).

“ July Debentures ” shall mean the Debentures.

“ July Purchase Agreement ” shall mean this Agreement.

“ July Purchasers ” shall mean the purchasers of July Debentures.

“ July Purchasers Intercreditor Agreement ” shall mean the intercreditor agreement in favor of the Purchasers in the form attached hereto as Exhibit H, among the July Purchasers and some or all of the holders of the Other Debentures.

“ July Senior Lender Intercreditor Agreement ” shall have the meaning set forth in “Senior Lender Intercreditor Agreements”

“ July Warrants ” shall mean the Warrants.

“ Legend Removal Date ” shall have the meaning ascribed to such term in Section 4.1(c).

“ Liens ” means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

“ March Purchase Agreement ” means the Securities Purchase Agreement, dated as of March 11, 2008, by and among the Company and each of the purchasers signatories thereto for the issuance of debentures and warrants.

 “ March Purchasers ” means the purchasers of the securities issued pursuant to the March Purchase Agreement and any successors in interest to any of the debentures and warrants issued pursuant to the March Purchase Agreement (by way of assignment or cancellation and reissuance of the same).

“ March Registration Rights Agreement ” means the Registration Rights Agreement, dated March 11, 2008, by and among the Company and each of the March Purchasers.

“ Material Adverse Effect ” shall have the meaning assigned to such term in Section 3.1(b).

“ Material Permits ” shall have the meaning ascribed to such term in Section 3.1(m).

“ Maximum Rate ” shall have the meaning ascribed to such term in Section 5.17.

“ November Purchase Agreement ” means the Securities Purchase Agreement, dated as of November 19, 2008, by and among the Company and each of the purchasers signatory thereto for the issuance of debentures and warrants.

“ November Purchasers ” means the purchasers of the securities issued pursuant to the November Purchase Agreement and any successors in interest to any of the debentures and warrants issued pursuant to the November Purchase Agreement (by way of assignment or cancellation and reissuance of the same).

“ November Purchasers Intercreditor Agreement” means the intercreditor agreement dated as of November 19, 2008, duly executed by the Company, each of the Purchasers and each of the November Purchasers and each of the March Purchasers party thereto.

“ November Senior Lender Intercreditor Agreement ” shall have the meaning set forth in “Senior Lender Intercreditor Agreements.”

“ Participation Maximum ” shall have the meaning ascribed to such term in Section 4.12(a).

“ Person ” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 “ Pre-Notice ” shall have the meaning ascribed to such term in Section 4.12(b).

“ Principal Amount ” means, as to each Purchaser, the amounts set forth below such Purchaser’s signature block on the signature pages hereto next to the heading “Principal Amount,” in United States Dollars, which shall equal such Purchaser’s Subscription Amount multiplied by 1.75.

“ Other  Debentures ” means the March Debentures, the November Debentures and the VPP Debentures.

 “ Pro Rata Portion ” shall have the meaning ascribed to such term in Section 4.12(e).

“ Proceeding ” means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.

“ Purchaser Party ” shall have the meaning ascribed to such term in Section 4.10.

“ Registration Statement ” means a registration statement filed pursuant to Section 4.18, registering the resale, by the Purchasers, of all of the Underlying Shares, or any portion thereof.

“ Required Approvals ” shall have the meaning ascribed to such term in Section 3.1(e).

“ Required Minimum ” means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable in the future pursuant to the Transaction Documents, including any Underlying Shares issuable upon exercise in full of all Warrants or conversion in full of all Debentures (including Underlying Shares issuable as payment of interest on the Debentures), ignoring any conversion or exercise limits set forth therein, and assuming that the Conversion Price is at all times on and after the date of determination 75% of the then Conversion Price on the Trading Day immediately prior to the date of determination.

“ Rule 144 ” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

“ SEC Reports ” shall have the meaning ascribed to such term in Section 3.1(h).

“ Securities ” means the Debentures, the Warrants, the Warrant Shares and the Underlying Shares.

“ Securities Act ” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“ Security Agreement ” means the Security Agreement, dated the date hereof, among the Company and the Purchasers, in the form of Exhibit E attached hereto.

“ Security Documents ” shall mean the Security Agreement, the Subsidiary Guarantees, the Intercreditor Agreement, and any other documents and filing required thereunder in order to grant the Purchasers a security interest in the assets of the Company and the Subsidiaries as provided in the Security Agreement, including all UCC-1 filing receipts.

“ Senior Debt ” shall have the meaning set forth in the July Senior Lender Intercreditor Agreement.

“ Senior Lender ” shall mean ACF CGS, L.L.C. as agent for itself and other persons participating in the Senior Debt.

“ Senior Lender Intercreditor Agreements ” means: (i) the Intercreditor Agreement, dated as of November 19, 2008 (“November Senior Lender Intercreditor Agreement”) among the Senior Lender, the Company and the holders of the March Debentures and November Debentures as of such date; (ii) the Intercreditor Agreement among the Senior Lender, the Company and the Holders of the Debentures dated on or about the date of this Agreement (“July Senior Lender Intercreditor Agreement”); and (iii) the VPP Senior Lender Intercreditor Agreement.

“ Senior Lender Purchasers ” means the purchasers of the securities issued pursuant to the Loan and Security Agreement dated as of November 19, 2008 by and among the Company and its Subsidiaries and ACF CGS, L.L.C. (the “ Senior Lender Loan Agreement ”).

“ Short Sales ” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). 

“ 67% Majority ”  shall mean the Holders of 67% or more aggregate principal amount of the Debentures issued pursuant to this Agreement and outstanding from time to time.

“ Subscription Amount ” means, as to each Purchaser, the aggregate amount to be paid for Debentures and Warrants purchased hereunder as specified below such Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,” in United States dollars and in immediately available funds.

“ Subsequent Financing ” shall have the meaning ascribed to such term in Section 4.12(a).

“ Subsequent Financing Notice ” shall have the meaning ascribed to such term in Section 4.12(b).

“ Subsidiary ” means any subsidiary of the Company as set forth on Schedule 3.1(a) and shall, where applicable, include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

“ Subsidiary Guarantee ” means the Subsidiary Guarantee, dated the date hereof, by each Subsidiary in favor of the Purchasers, in the form of Exhibit F attached hereto.

“ Trading Day ” means a day on which the principal Trading Market is open for trading.

“ Trading Market ” means the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the American Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTC Bulletin Board or the Pink Sheets.

 “ Transaction Documents ” means this Agreement, the Debentures, the Warrants, the Security Agreement, the Subsidiary Guarantee, the Senior Lender Intercreditor Agreement, the March Purchasers Intercreditor Agreement, the November Purchasers Intercreditor Agreement, the Consent, Waiver and Amendment Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

“ Transfer Agent ” means Continental Stock Transfer & Trust Company, the current transfer agent of the Company with a mailing address of 17 Battery Place, New York, New York 10004 and a facsimile number of 212-509-5150, and any successor transfer agent of the Company.

“ Underlying Shares ” means the shares of Common Stock issued and issuable upon conversion or redemption of the Debentures and upon exercise of the Warrants and issued and issuable in lieu of the cash payment of interest on the Debentures in accordance with the terms of the Debentures.

“ Variable Rate Transaction ” shall have the meaning ascribed to such term in Section 4.13(b).

” Vendor Payment Plan”   shall mean the plan put in place by the Company (on behalf of itself and its subsidiaries) and certain of the trade creditors of the Company and/or its subsidiaries on or before the date of this Agreement and as amended from time to time by the Company with the consent of the Collateral Agent, for the reduction of past due obligations of the Company and its subsidiaries to such creditors.

“ VPP Debentures ” shall mean the debentures issuable by the Company pursuant to the VPP Purchase Agreement.

“ VPP Warrants ” shall mean the warrants issuable to the purchasers of VPP Debentures.

“ VPP Purchase Agreement ” shall mean the purchase agreement pursuant to which certain of the vendors to the Company are issued VPP Debentures and corresponding VPP Warrants, permitting aggregate subscriptions for up to $2,500,000 of cash subscriptions (representing aggregate OID principal amount of up to $1,625,000, for cumulative principal amount of up to $4,125,000).

“ VPP Purchasers ” shall mean the purchasers of debentures issued pursuant to the VPP Purchase Agreement.

“ VPP Senior Lender Intercreditor Agreement ” shall mean the intercreditor agreement among the Senior Lender, the Company and its subsidiaries, and the VPP Purchasers.

“ VWAP ” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. New York City time to 4:02 p.m. New York City time); (b)  if the OTC Bulletin Board is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the OTC Bulletin Board; (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported; or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

“ Warrants ” means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be exercisable immediately and have a term of exercise equal to 5 years from the date of the Authorized Share Approval, in the form of Exhibit C attached hereto.

“ Warrant Shares ” means the shares of Common Stock issuable upon exercise of the Warrants.

2.1            Closing .  On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase: (i)  up to $7,000,000, in the aggregate, in principal amount of the Debentures (with an aggregate Subscription Amount of up to $4,000,000—the “First Tranche Subscription Amount,” with the corresponding Debentures being the “First Tranche Debentures”); and (ii) no later than five (5) business days following the delivery by the Company of the Delay Draw Notice, up to $3,500,000, in the aggregate, in principal amount of the Debentures (with an aggregate subscription amount of $2,000,000- the “Second Tranche Subscription Amount,” with the corresponding Debentures being the “Second Tranche Debentures”).  With respect to the First Tranche Debentures: (i) $700,000 of the original principal amount (representing $400,000 of aggregate Subscription Amount) shall be issued to those purchasers of March Debentures and November Debentures who execute the Consent, Waiver and Amendment Agreement (and allocated among them pro rata as shown on Schedule 2.1 hereof), and shall be issued to each such holder on delivery of a counterpart executed copy by such holder of his, her or its counterpart copy of the Consent, Waiver and Amendment Agreement; and (ii) $175,000 of the original principal amount (representing $100,000 of aggregate Subscription Amount) shall be issued to Aequitas Capital Management, Inc. (“Aequitas”) or its designee upon the initial issuance of Debentures pursuant to this Agreement, and shall be credited against $100,000 of monies owing by the Company to Aequitas. The Second Tranche Debentures shall be substantially identical to the Debentures, except that the issuance date shall be the date of funding of the Second Tranche Subscription Amount by the applicable purchaser thereof.  Each Purchaser who has funded cash toward the purchase of the initial $3,500,000 of cash funding (such Purchasers being the “Cash Purchasers” and their respective percentages of the cash funding being as to each the “Cash Purchaser Percentage”)shall deliver to the Company within one business day following execution hereof via wire transfer or a certified check, immediately available funds equal to its cash First Tranche Subscription Amount and the Company shall deliver to each Purchaser its respective Debenture and a Warrant, as determined pursuant to Section 2.2(a), and the Company and each such Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing.  Upon satisfaction of the conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Shefsky & Froelich Ltd. or such other location as the parties shall mutually agree.  Attached hereto as Exhibit 2.1 is a schedule of certain identified non-recurring revenue items that the Company and its subsidiaries anticipate receiving on or before July 31, 2009 (the “Non-recurring Receipts”).  To the extent that collections by the Company of Non-recurring Receipts are less than $2,000,000 by August 14, 2009, then the Company shall on that date send a notice to the Cash Purchasers (the “Delay Draw Notice”) requiring each of them to fund up to their respective Cash Purchaser Percentage of the shortfall of such collections within five (5) business days of delivery of the Delay Draw Notice (the amount required of each Cash Purchaser being the “Delay Draw Pro Rata Amount”).  Each Cash Purchaser shall be required to deliver to the Company its Delay Draw Pro Rata Amount within five (5) business days of receipt of the Delay Draw Notice by wire transfer or certified check, and upon funding the Company shall issue an additional Debenture in the principal amount of 1.75 times the amount funded by the Cash Purchaser and a Warrant as determined in Section 2.2.  In the event that a Cash Purchaser fails to timely deliver its Delay Draw Pro Rata Amount (the “Unfunded Delay Draw”), the Company shall have the right to enforce the funding obligation, and in addition, shall have the right to offer the Unfunded Delay Draw to any other person or entity, and in the event it is funded by any other person or entity before funding of the same (the “New Purchaser”) by the defaulting Cash Purchaser (“Defaulting Purchaser”), then the New Purchaser shall be issued the corresponding Debenture and Warrant, and in addition, the Defaulting Purchaser shall forfeit to the New Purchaser its right to payment of principal of its First Tranche Debenture in excess of the Subscription Amount paid by the Defaulting Purchaser for its First Tranche Debenture (the “Forfeited Principal Amount”).  The Company shall provide to the Cash Purchasers other than the Defaulting Purchaser a 5 day right of first refusal to purchase their pro rata shares (based on their respective Cash Purchaser  Percentages) of the Unfunded Delay Draw (and Forfeited Principal Amount) allocable to the Defaulting Purchaser, which notice shall be delivered no later than two business days following the due date for payment by the New Purchaser and shall allocate subscription rights thereto accordingly, with the right thereafter to sell any unsubscribed for amount of the Unfunded Delay Draw, to any person or entity, subject to compliance with the requirements of Section 2.3(c) below.   In the event the Unfunded Delay Draw is purchased by more than one person or entity, then the rights thereto (and corresponding Forfeited Principal Amount) shall be allocated pro rata based upon the respective amounts thereof purchased by the purchasers.  Each Defaulting Purchaser agrees to cooperate fully with the Company to exchange its First Tranche Debenture for a new substituted debenture that will be devoid of the Forfeited Principal Amount (which will be assigned to the new purchaser(s) with a substitute debenture substantially identical to the form of First Tranche Debenture, except that the Forfeited Principal Amount shall not accrue interest through the maturity date).  The Company further agrees that provided it is permitted to do so by the Senior Lender, the Company will refund to each purchaser (as a principal pay down) of a Second Tranche Debenture his, her or its pro rata share (based on total principal amount of Second Tranche Debentures outstanding) of any collections that the Company receives of Non-recurring Receipts following the issuance of the Second Tranche Debentures.

2.2            Deliveries .

(a)           On the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

(i)           this Agreement duly executed by the Company;

(ii)          a Debenture with a principal amount equal to such Purchaser’s Subscription Amount multiplied by 1.75, registered in the name of such Purchaser;

(iii)         a Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 75% of such Purchaser’s Subscription Amount divided by $0.24, with an exercise price equal to $0.24, subject to adjustment therein;

(iv)         the Security Agreement, duly executed by the Company and each Subsidiary, along with all of the Security Documents, including the Subsidiary Guarantee, duly executed by the parties thereto;

(v)          a form of consent, waiver and amendment agreement issued by: (A) the Senior Lender Purchasers in the form attached as Exhibit I-1 (“Senior Lender Second Amendment and Waiver”); and (B) holders of not less than 67% of the outstanding principal amount of the March Debentures and the November Debentures in the form attached as Exhibit I-2 (“Other Debenture Holders’ Consent, Wavier and Amendment Agreement”), consenting to the transactions contemplated herein;

(vi)           the July Senior Lender Intercreditor Agreement, duly executed by the Company and the July Purchasers; and

(vii)          the VPP Senior Lender Intercreditor Agreement, duly executed by the Company and each of the VPP Purchasers.

(viii)        payment of $100,000 toward an aggregate $300,000 Collateral Agent fee to Aequitas; in addition, the Company agrees to pay an additional $100,000 on each of the 3 month anniversary and the 6 month anniversary of the Closing Date to satisfy the Collateral Agent fee in full; this fee shall be in lieu of any other fees payable pursuant to its existing consulting agreement with the Company.  The Company has paid a $50,000 deposit to Aequitas prior to the date of this Agreement, to be applied toward expenses incurred in connection with the Transaction Documents, with any remainder as of the Closing Date to be credited toward the initial $100,000 payment due on the Closing Date; in the event that these expenses exceed $50,000, the excess will be billed by the Collateral Agent to the Company.

(b)          On the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following (unless waived by the Company with the consent of the Collateral Agent):

(ii)           such Purchaser’s cash First Tranche Subscription Amount by wire transfer to the account as specified in writing by the Company

(iii)          the Security Agreement duly executed by such Purchaser;

(iv)          the July Senior Lender Intercreditor Agreement duly executed by such Purchaser; and

(v)           the VPP Senior Lender Intercreditor Agreement duly executed by such Purchaser .

(c)          In the event that the Delay Draw Notice is issued by the Company, promptly following the Company’s receipt of subscription proceeds with respect to each Second Tranche Subscription Amount (or Unfunded Delay Draw with respect to the obligations of any Defaulting Purchaser), the Company shall deliver to the purchaser of the Second Tranche Debenture the corresponding Second Tranche Debenture Warrant and appropriate evidence of the rights to the Forfeited Principal Amount (if applicable).  To the extent that the purchaser of a Second Tranche Debenture is not a Purchaser from the initial Closing, then such purchaser shall execute a counterpart copy of this Agreement and of the Security Agreement, the July Senior Lender Intercreditor Agreement and the July Intercreditor Agreement,   as a condition precedent to acquiring the Second Tranche Debenture.

2.3           Closing Conditions .

(a)             The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

(i)           the accuracy in all material respects on the Closing Date of the representations and warranties of the Purchasers contained herein;

(ii)          all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and

(iii)         the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.

(b)          The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met or waived by the Purchasers subscribing for at least $2,000,000 of Cash Subscription Amount:

(i)          the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained herein;

(ii)         all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;

(iii)        the delivery of the consent, waiver and amendment agreement, in the form attached hereto as Exhibit I-1 , duly executed by the parties named therein;

(iv)        there shall have been no Material Adverse Effect with respect to the Company since the date hereof;

(v)         from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission  and, at any time prior to the Closing Date, a banking moratorium shall not have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of each Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing;

(vi)        subscriptions for no less than $3,500,000 of First Tranche Subscription Amount must have been received by the Company, and the  holders of Other Debentures holding not less than 67% of the outstanding Other Debentures principal amount must have executed the Consent, Waiver and Amendment Agreement;

(vii)       the Company shall have documented a restructuring plan with the holders of not less than 60% of outstanding accounts payable of the Company which are over 60 days outstanding;

(viii)     the Company shall have delivered to Aequitas a 13 week cash flow model within 14 days prior to the Closing Date;

(ix)        Senior Lender and the Company shall have amended the Senior Lender Loan Agreement with respect to the covenants  in a manner satisfactory to the Company and Aequitas and the loan subject to the Senior Lender Loan Agreement shall continue to have a maturity date no earlier than its original maturity date, and with the Senior Lender having waived all know defaults under the Senior Loan Agreement (including with respect to the forbearance agreement dated as of July 7, 2009—“Forbearance Agreement”);

(x)         the $1,000,000 deposit provided by the Company to Senior Lender pursuant to the Forbearance Agreement shall remain available for return to Company in accordance with the terms and conditions set forth in the Senior Lender Second Amendment and Waiver;

(xi)        the Company’s board of directors shall have approved the Transaction Documents, the Vendor Payment Plan, the Company’s most recent 13 week cash model, the Company’s most recent 18 month forecast and the amendments to the Senior Lender Loan Agreement set forth in clause (xi) immediately above; and

(xii)       The Company shall have met any other conditions reasonably requested by Aequitas.

(a)            Subsidiaries .  All of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a) .  Except as set forth on Schedule 3.1(a) , the Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities.

(b)            Organization and Qualification .  The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and except as noted in Schedule 3.1(b), in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.  Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.  Each of the Company and the Subsidiaries is duly qualified to conduct business and except as noted in Schedule 3.1(b) is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a “ Material Adverse Effect ”) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

(c)            Authorization; Enforcement .  The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.  The execution and delivery of each of the Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders in connection therewith other than in connection with the Required Approvals.  Each Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(d)            No Conflicts .  Subject to receipt of the Senior Lender Consent, Waiver and Amendment Agreement and the Other Debenture Holders’ Consent, Waiver and Amendment Agreement, the execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the consummation by it of the other transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, (iii) subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

(e)            Filings, Consents and Approvals .  The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.6, (ii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the Underlying Shares for trading thereon in the time and manner required thereby, and (iii) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively, the “ Required Approvals ”).

(f)            Issuance of the Securities .  The Securities (other than the Underlying Shares) are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.  Subject only to the Authorized Share Approval, the Underlying Shares, when issued in accordance with the terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.

(g)            Capitalization .  The capitalization of the Company is as set forth on Schedule 3.1(g) , which Schedule 3.1(g) shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant to the Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act or as reflected on Schedule 3.1(g) .  Except as set forth on Schedule 3.1(g)(i) , no Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.  Except as a result of the purchase and sale of the Securities or on Schedule 3.1(g) , there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. Except as set forth on Schedule 3.1(g)(ii) , the issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.  Except as set forth on Schedule 3.1(g)(iii) , no further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities.  There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.

(h)            SEC Reports; Financial Statements .  Except for the Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ended March 31, 2009, which are unfiled as of the date hereof, the Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the “ SEC Reports ”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.  Except as noted on Schedule 3.1(h) , or as otherwise disclosed in subsequently filed SEC Reports filed prior to the date hereof, as of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed except as otherwise disclosed in subsequently filed SEC Reports filed prior to the date hereof, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.  Except as described on Schedule 3.1(h) , the Company has never been an issuer subject to Rule 144(i) under the Securities Act.  Except as otherwise disclosed in Schedule 3.1(h) or subsequently filed SEC Reports filed prior to the date hereof, the financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.  Except as otherwise disclosed in Schedule 3.1(h) or subsequently filed SEC Reports filed prior to the date hereof, such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved (“ GAAP ”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

(i)            Material Changes .  Other than as set forth on Schedule 3.1(i) , since the date of the latest audited financial statements included within the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice or in connection with the transaction contemplated by this Agreement and (B) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information.  Except for the issuance of the Securities contemplated by this Agreement and the other transactions contemplated by the Transaction Documents or as set forth on Schedule 3.1(i) , no event, liability or development has occurred or exists with respect to the Company or its Subsidiaries or their respective business, properties, operations or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.

(j)            Litigation .  There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “ Action ”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect, except as noted in Schedule 3.1(j) .  Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty, except as set forth on Schedule 3.1(j) .  There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company.  The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

(k)            Labor Relations .  No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company which could reasonably be expected to result in a Material Adverse Effect.  None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good.  No executive officer, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters.  Except as disclosed on Schedule 3.1(k) , the Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(l)            Compliance .  Except as set forth on Schedule 3.1(l) , neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any order of any court, arbitrator or governmental body or (iii) is or has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws applicable to its business and all such laws that affect the environment, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.

(m)            Regulatory Permits .  Except as disclosed on Schedule 3.1(m) , the Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“ Material Permits ”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.

(n)            Title to Assets .  Except for the liens set forth on Schedule 3.1(n) , the Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties.  Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.

(o)            Patents and Trademarks .  The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights as described in the SEC Reports as necessary or material for use in connection with their respective businesses and which the failure to so could have a Material Adverse Effect (collectively, the “ Intellectual Property Rights ”).  Neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes upon the rights of any Person. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights.  The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(p)            Insurance .  The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage in the amount of $10.0 million.  Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.

(q)            Transactions with Affiliates and Employees .  Except as set forth in the SEC Reports, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Subsidiary (other than for services